Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. will host a conference call on May 9, 2024, to discuss its Q1 2024 financial results and recent business developments. The biopharmaceutical company's innovative INVYMAB platform aims to provide protection against serious viral diseases, starting with SARS-CoV-2. Recently, Invivyd received emergency use authorization from the FDA for its first monoclonal antibody. The call will be accessible via a webcast for interested analysts and investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is poised to discuss promising financial results for Q1 2024.
  • The company received EUA from the FDA for its first monoclonal antibody.
  • The INVYMAB platform allows rapid adaptation to viral threats.

Full Press Release Details

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Frequently Asked Questions

When is Invivyd's financial conference call scheduled?

Invivyd's financial conference call is on May 9, 2024, at 4:30 p.m. ET.

What will be discussed during the conference call?

The call will cover Invivyd's Q1 2024 financial results and recent business highlights.

How can I register for the Invivyd conference call?

Listeners can register for the webcast through a provided link.

What is Invivyd's focus as a biopharmaceutical company?

Invivyd focuses on delivering protection from serious viral infectious diseases.

What technology does Invivyd use for antibody development?

Invivyd uses the INVYMAB™ platform for rapid monoclonal antibody generation.

Last updated: May 2, 2024